The ubiquitin proteasomal system: a potential target for the management of Alzheimer’s disease

Kundlik Gadhave a, f, Nityanand Bolshe b, #, Ashutosh Ahire a, Rohit Pardeshi b, Krishan Thakur b, Cristiana Trandafir c, Alexandru Istrate c, Sahabuddin Ahmed a, Mangala Lahkar a, b, Dafin F. Muresanu c, d, a, *, Maria Balea d

a Laboratory of Neurobiology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati, Assam, India
b Institutional Level Biotech hub (IBT hub), Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati, Assam, India
c Faculty of Medicine, University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania
d Department of Clinical Neurosciences, University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania
e “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania

Received: September 14, 2015; Accepted: January 17, 2016

Abstract

The cellular quality control system degrades abnormal or misfolded proteins and consists of three different mechanisms: the ubiquitin proteasomal pathway (26S pathway or UPP), autophagy and molecular chaperones. Any disturbance in this system causes proteins to accumulate, resulting in neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease and prion or polyglutamine diseases. Alzheimer’s disease is currently one of the most common age-related neurodegenerative diseases. However, its exact cause and pathogenesis are unknown. Currently approved medications for AD provide symptomatic relief; however, they fail to influence disease progression. Moreover, the components of the cellular quality control system represent an important focus for the development of targeted and potent therapies for managing AD. This review aims to evaluate whether existing evidence supports the hypothesis that UPS impairment causes the early pathogenesis of neurodegenerative disorders. The first part presents basic information about the UPS and its molecular components. The next part explains how the UPS is involved in neurodegenerative disorders. Finally, we emphasize how the UPS influences the management of AD. This review may help in the design of future UPS-related therapies for AD.

Keywords: ubiquitin ● Alzheimer’s disease ● amyloid β ● chaperones

Introduction

Biosynthesized proteins often misfold because of destabilizing mutations, stress or metabolic changes [1] and cannot perform their biological functions. Protein misfolding is prevented by the cellular quality control system, which consists of the ubiquitin proteasomal pathway (26S pathway or UPP), autophagy and molecular chaperones [2, 3]. These mechanisms, which are often referred to as the cellular proteostasis network, prevent the accumulation of toxic levels of unfolded or misfolded proteins [4] by breaking the proteins down into polypeptide chains [5, 6]. Any disturbance in this system causes pro-
teins in different parts of the body to accumulate and promotes severe neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and prion or polyglutamine diseases [2, 7].

Presently, AD is one of the best described age-related neurodegenerative diseases. However, its potential cause is not fully understood. Alzheimer's disease is characterized by a progressive loss of memory and object recognition, dementia and changes in behavior and speech. It is associated with the synthesis of defective proteins, errors in their transport to membranes and oxidative damage. Researchers have suggested that the aggregation of amyloid beta (Aβ) initiates this disease. Amyloid beta is formed when amyloid precursor protein (APP) [4, 6] undergoes successive enzymatic cleavages and is transported into the extracellular space. Overproduction or defective clearance of Aβ causes it to progressively accumulate. Amyloid beta self-aggregates into oligomers, which obstruct proteosome function and disturb neuronal processes. Furthermore, Aβ inhibits the proteasomal pathway and promotes the formation and accumulation of hyperphosphorylated tau, a highly soluble microtubule-binding protein [8]. Normally, tau stabilizes the microtubule network within axons and facilitates the axonal transport of organelles, neurotransmitters and other cellular constituents that act as trophic factors [9, 10]. Hyperphosphorylated tau self-aggregates into neurofilillary tangles (NFTs) and impairs axonal transport and neuronal function [8].

Protein degradation is primarily performed by proteasomes in the cytosolic and nuclear compartments [11]. Changes in UPP-based protein degradation lead to pleiotropic effects, such as neurodegeneration, synaptic dysfunction and neuron death [12]. Recently, many studies have suggested that UPP affects the pathogenesis of AD [12, 13]. First, ubiquitinated proteins are present in AD. In addition, misfolded proteins within all tissues are normally degraded by the UPP [8, 9]. However, the exact underlying mechanism of this process continues to be investigated.

The ubiquitin proteasomal system

Intracellular protein degradation is a selective process [14] that, in eukaryotic cells, is catalyzed by proteasome, the major component of the ubiquitin proteasomal system (UPS) [8, 15]. Ubiquitin proteasomal system-mediated degradation is the primary proteolytic mechanism for normal and abnormal synaptic proteins. The UPS includes five steps: activation, conjugation, recognition, ubiquitin removal by specific deubiquitinating enzymes (DUBs) and substrate degradation by the proteasome [16, 17].

The UPS controls protein degradation by proteasome-mediated proteolysis and regulates protein function via multiple types of ubiquitination. The UPS degrades more than 80% of normal and abnormal intracellular proteins [18]. Within tissues, most intracellular proteins are degraded by the UPS, whereas extracellular proteins and several proteins on the cell surface are endocytosed and degraded via lysosomes [19]. The UPS controls many cellular processes: the cell cycle, DNA transcription and repair, apoptosis and quality control [20, 21]. It also maintains proteostasis during aging and disease and prevents protein misfolding and aggregation [22].

Ubiquitination and deubiquitination

Ubiquitin is a 76-amino-acid protein with a molecular weight of 8.5 kD that is present in all tissues in a free or covalently conjugated form. Ubiquitination is a reversible process [23] that consists of the covalent attachment of the glycine residue of ubiquitin to a lysine residue of the target protein via an isopeptide bond through the actions of ubiquitin activating (E1), conjugating (E2) and ligating (E3) enzymes [2, 24]. Recently, the activity of an E4 enzyme was described. E1 and E2 enzymes prepare ubiquitin for conjugation. E3 enzymes recognize the specific substrate and catalyze the transfer of activated ubiquitin to the substrate [19, 25]. E4 enzymes catalyze the conjugation of additional ubiquitin monomers to form a polyubiquitin chain, usually through lysine 48 (K48) linkages [12] (Fig. 1). For 26S proteasome degradation, a polyubiquitin chain is made of four or more ubiquitin proteins that target a single substrate [8]. There are two types of E3 ligases: HECT (homologous to E6-associated protein C-terminus) and RING-finger/adapter. Only the HECT domain E3 ligase forms a covalent bond with ubiquitin through a thioester intermediate during polyubiquitination (the transfer of ubiquitin to the substrate) of abnormal proteins. The RING-finger E3 ligase directly transfers ubiquitin from its associated E2 enzyme to the substrate [16]. The fate of ubiquitinated proteins depends on the type of linkage with ubiquitin (K48, K63, K6, K11, K27, K29 and K33). K48-linked polyubiquitinated proteins are generally degraded through the proteasomal pathway, whereas K63-linked polyubiquitinated proteins are degraded via the lysosomal pathway [26]. The different types of ubiquitin linkage exhibit the following associations: K6 with DNA repair, K11 with endoplasmic reticulum (ER)-associated protein degradation and cell cycle regulation, K27 with ubiquitin fusion and degradation, K29 with lysosomal degradation and K33 with kinase modification [22]. After the proteasome recognizes the polyubiquitinated substrate, DUBs deubiquitinate the polyubiquitin chain at different levels of the UPS. Deubiquitination may occur before or after DUBs recognize the substrate on the 26S proteasome [14]. After they recognize the substrate, the catalytic core degrades the substrate, and the DUBs recycle ubiquitin and preserve monoubiquitin for additional ubiquitination [14]. Deubiquitination is necessary when newly translated ubiquitin binds with the C-terminal end of amino acids or is cleaved by ubiquitin C-terminal hydrolase 1 (UCHL1). Approximately, 100 DUBs are found in eukaryotes [27]. Of them, 27 are in the nervous system, and seven are in the proteasomal system [14] (Fig. 2). Deubiquitinating enzymes are grouped into five different classes: (i) ubiquitin C-terminal hydrolases (UCHs), e.g. UCHL1, UCHL3, and UCHL5/UCH37; (ii) ubiquitin-specific proteases (USPs), e.g. USP7, USP9x, and USP14; (iii) Machado-Joseph disease protease, e.g. ataxin-3; (iv) otubain proteases (OTUs), e.g. otubain 1 and otubain 2 and (v) metallo-enzymes (JAMMs), e.g. PSMD14/Rpn11 and JAB1/MPN/Mov34 [14, 28].

Ubiquitin chain trimming promotes or inhibits proteasomal degradation. The enzymes involved in this process (especially DUBs) are
potential therapeutic targets for the regulation of proteasomal degradation and the treatment of AD [14, 27].

The 26S proteasome

The proteasome is a multisubunit protein complex that includes parts of the cytoplasm and the nucleus. There are several thousands of proteasomes, which are responsible for intracellular protein degradation [29] of normal and misfolded cytoplasmic proteins [30]. Within the cytoplasm, the proteasome is associated with the centrosome, the cytoskeletal network and the outer surface of the ER, whereas in the nucleus, it is present throughout the nucleoplasm [31]. Two types of proteasomes exist in eukaryotes: a smaller 20S proteasome that degrades unfolded proteins and a larger 26S proteasome that degrades folded proteins in an ATP-dependent or -independent manner [30, 32].

A modification of the 26S proteasome, the immunoproteasome, is also involved in the pathogenesis of AD via neuroinflammation [33, 34]. The 26S proteasome is a 2.5-MDa multicatalytic protease complex that recognizes and degrades ubiquitin-tagged substrates [19]. It consists of a 20S core particle (CP) (700 kD) that is associated with one or two 19S regulatory particles (RPs) [18, 20]. After the substrates are ubiquitinated, the 26S proteasome recognizes them in the presence of the lid subunits of the 19S RP, Rpn10/S5a and Rpn13/Adrm1 [27]. Then, the ubiquitinated substrates are deubiquitinated by Rpn11 in the presence of the DUBs USP14, UCHL5, PSMD14, UCHL1, Ataxin-3, USP7 and USP9x [8, 14]. The proteins are then unfolded through ATP hydrolysis in the 19S RP and translocated into the 20S CP for degradation [29].

The 19S RP is composed of two subcomplexes (lid and base), both of which contain at least 19 individual subunits. These subunits are responsible for specific substrate recognition, deubiquitination, and unfolding and translocation of the substrate into the proteolytic chamber for degradation [29]. The lid consists of nine non-ATPase subunits (Rpn3, 5-9, 11, 12, and 15), and the base consists of six ATPase (Rpt1-6) and four non-ATPase (Rpn1, 2, 13, and 10) subunits [20] (Fig. 3). The primary function of the lid is to deubiquitinate the substrate: Rpn11 in the lid displays deubiquitinating activity [20] and aids ubiquitin recycling [24]. The base subcomplex is composed of six homologous ATPase subunits (Rpt1-6) and 4 non-ATPase subunits (Rpn1, 2, 10 and 13). The base recognizes ubiquitin, binds to the substrate, promotes its unfolding and opens the channel of the 20S CP [35]. The Rpn10/S5a and Rpn13/Adrm1 subunits of the base act as two integral receptors and coordinate binding of the proteasome to polyubiquitin chains [27]. Rpn10 also stabilizes the bond between the lid and the base [20]. Rpn2 is the largest subunit of the proteasome and stabilizes the 19S complex [27].

Fig. 1 General outline of ubiquitination. Ubiquitination is the covalent attachment of the glycine residue of ubiquitin to the lysine residue of the target protein via an isopeptide bond. This process is mediated by E1, E2 and E3 enzymes. E1 ligases forms thioester bonds with ubiquitin, which is subsequently transferred to E2 ligases through a thioester linkage. E3 ligases are grouped into two types: HECT type and RING-finger/adaptor type. Only the HECT domain E3 ligase forms a covalent bond with ubiquitin during polyubiquitination of abnormal proteins, whereas the RING-finger E3 ligases directly transfer ubiquitin from the associated E2 enzyme to the substrate protein. Proteins can be mono-, multiple- or poly-ubiquitinated. Mono- and multiple-ubiquitinated proteins are degraded by lysosomes (autophagy), whereas the degradation of polyubiquitinated proteins depends on the type of ubiquitin linkage (K48, K63, K6, K11, K27, K29 and K33). K48-linked polyubiquitinated proteins are generally degraded by the proteasomal pathway. Polyubiquitination via K6 is associated with DNA repair; via K11, with endoplasmic reticulum-associated protein degradation and cell cycle regulation; via K27, with ubiquitin fusion degradation; via K29, with lysosomal degradation; and via K33, with kinase modification. DUBs remove ubiquitin from the substrate protein, and the monomers are recycled.
In several cases, the 19S RP can be replaced by the PA28/11S regulatory complex, which contains a single ring of seven subunits [36]. Replacing three catalytic subunits in a standard proteasome forms an immunoproteasome [37]. The immunoproteasome utilizes the 11S RP instead of the 19S RP to facilitate 20S gate opening and to stimulate substrate unfolding and translocation. In addition, the immunoproteasome has increased chymotrypsin-like and trypsin-like activities because of the six different ATPases (Rpt1-6) at the base of the 19S RP that interact with the 20S catalytic chamber [38].

The 20S CP, also known as the 20S 'core' proteasome complex or 20S proteasome [39], contains peptidases that function through a threonine active site [40]. Unlike the 26S proteasome, the 20S CP actively recognizes and degrades substrate proteins and is not reversibly inactivated by mild oxidative stress [41]. In addition, the 20S CP can only degrade proteins that are already unfolded, whereas the 26S proteasome can degrade folded and functional proteins [42]. The 20S CP is a barrel-like structure and consists of four stacked heptameric rings (α, β, β, and α) [29]. The outer two α-rings consist of seven homologous subunits (α1-α7), and the inner two β-rings consist of seven homologous subunits (β1-β7) [29]. The β-ring contains a wide pore at its center in which proteolysis occurs, and the α-ring contains a narrow pore that allows the translocation of only unfolded proteins into the 20S CP [29]. The two β-rings in the 20S CP perform six proteolytic activities, two caspase-like, two trypsin-like and two chymotrypsin-like, which are performed by the β1, β2 and β5 subunits respectively [43]. A docking study [29] demonstrated that the binding of the 19S RP to the 20S CP occurs through an L-shaped link between the base of the 19S RP and the α2 subunit of the 20S CP. This link forms between the putative ATPase densities and the side of the α2 subunit of the 20S CP [9, 44]. Three additional links form between the 19S RP and the 20S CP. They are parallel to the long axis of the proteasome and extend from the putative ATPase region of the 19S RP to A5, A6 and the interface between A7 and A1 of the 20S CP. When the 19S RP binds to the 20S CP, the gate to the proteolytic chamber is opened through the displacement of the subunit within the α-ring of the 20S CP [29, 45]. The 20S core complex performs various catalytic activities, including cleaving the carboxy-terminal side of hydrophobic, basic or acidic residues [46]. 20S CP is activated by the ATPases and archaeal proteasome-activating nucleotide (PAN), which consists of peptides with a C-terminal hydrophobic tyrosine-x (HbYX) motif [24]. The N-terminal tails of the α-subunits of the 20S CP form a gate that opens when the HbYX peptide of the ATPase binds to the pockets of the 20S α-ring [47]. The C-terminal peptides of the ATPases Rpt2 and Rpt5 induce and regulate gate opening [24,48]. The regulatory peptides of the PAN C-terminus bind to the inner subunit pockets and open the gate of the 20S CP so that the substrate can enter the proteolytic chamber [24].

Fig. 2 The deubiquitination process. Different types of deubiquitinase enzymes (DUBs) mediate the degradation of misfolded proteins. Newly translated ubiquitin (Ub) that is fused with the C-terminal end of amino acids is cleaved by DUBs, such as UCHL1. UCHL1 maintains the pool of mono-Ub and supplies ubiquitin for misfolded protein ubiquitination. Ubiquitin enzymes (E1, E2, and E3 enzymes) form the polyubiquitin chain on substrate proteins by adding mono-Ub. The polyubiquitinated chain is modified by DUBs, such as ataxin-3, to ensure correct recognition of the substrate proteins by the 26S proteasome. The mono-Ubs are again recycled back into the pool of mono-Ub. DUBs, including USP14, work in two ways: (i) USP14 rescues polyubiquitinated proteins from degradation by the 26S proteasome, whereas DUBs such as USP7, ataxin-3 and USP9X facilitate the deubiquitination of poly-Ub chains and the recycling of mono-Ubs back into the pool of mono-Ub; and (ii) USP14 may also work in combination with other DUBs including PSMD14 and UCHL5, on the 26S proteasome to degrade misfolded proteins into small peptides. The poly-Ub chain is disassembled to mono-Ubs that are recycled back into the pool of mono-Ub.

© 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
The 26S proteasome binds polyubiquitinated misfolded proteins, deubiquitinates them, unfolds misfolded proteins, opens the α-gate of the 20S CP and subsequently degrades the misfolded proteins [35]. Ubiquitin affects substrate susceptibility to proteasomal degradation in two ways: the ubiquitination level of the substrate promotes proteasome-substrate interactions, and the ubiquitin chain structure influences substrate translocation to the 20S CP [49].

The ubiquitin proteasomal pathway in neurodegenerative disorders

Neurodegenerative diseases are characterized by abnormal deposition of insoluble protein aggregates or inclusion bodies within neurons [50]. Many of them are caused by the accumulation of abnormal, misfolded or aberrant proteins [51]; protofibrillar formation [52]; UPS dysfunction [53]; excitotoxic insult [54, 55]; oxidative and nitrosative stress [56]; mitochondrial injury [57]; synaptic failure [58] or altered metal homeostasis [59]. The UPP controls many of these processes in the nervous system. Several of its components are linked to synaptic dysfunction and genetic mutations that lead to neuronal disorders [50]: UPS impairment has been associated with synaptic dysfunction in AD, PD, Huntington’s disease (HD), schizophrenia, amyotrophic lateral sclerosis, ataxia, Angelman syndrome, Wallerian degeneration and gracile axonal dystrophy [50, 60]. Ubiquitinated protein aggregates cause UPS dysfunction or structural changes in protein substrates that prevent their recognition and degradation. This loss of degradation has pleiotropic effects on neurons, such as cell death, degeneration and synaptic malfunction [50]. Synaptic plasticity impairment and its connection to the UPP have been more extensively studied in AD than in PD and HD [60].

Alzheimer’s disease is a progressive neurodegenerative disorder that is also the most frequent cause of dementia. It is characterized by the intracellular accumulation of Aβ oligomers and hyperphosphorylated tau and by the extracellular accumulation of high-molecular-weight deposits of Aβ peptides in fibrillar forms. These accumulations result in memory loss and severe cognitive decline [22, 50]. Via the 26S proteasome, the UPP regulates Aβ metabolism and tau degradation [22]. Its impairment in the neurons of AD patients causes ubiquitinated proteins to accumulate.
and the combinations of proteasome subunits to change [22, 60], which decreases proteasomal activity, decreases α-secretase activity and produces Aβ [22] (Fig. 4). Alzheimer's disease is characterized by progressive degeneration and loss of cortical and limbic neurons. Amyloid beta peptides form senile plaques in the extracellular space, and NFTs are present intracellularly [61]. Proteasomal activity is decreased in the parahippocampal gyrus, the superior and middle temporal gyri and the inferior parietal lobe, suggesting that the UPP may be involved in the pathogenesis of AD [62].

Treatment strategies for Alzheimer’s disease

Protein misfolding and changes in cellular protein homeostasis are the primary causes of AD. Currently approved medications for treating AD provide symptomatic relief but fail to influence disease progression [63]. In the last 10 years, drug discovery has been directed towards developing disease-modifying agents. In fact, more than 200 medications are currently in phase 2 and 3 clinical trials [64]. These compounds can be largely categorized into anti-amyloid agents and medications that target other pathophysiological pathways (Tables 1–7). Developments in AD prevention and treatment include anti-amyloid drugs; methods to hyperphosphorylate tau; and neuroprotective and neurotrophic approaches, such as those involving neurotrophins, neurotrophic factors and stem cells [65]. Neurotrophic agents such as cerebrolysin modulate the apoptosis rate of neurons in patients affected by neurodegenerative diseases and are a novel treatment option for AD [66]. The accumulation of toxic amyloid is regulated by the quality control systems of the cell (molecular chaperones, autophagy and the UPS) [22]. Targeting different components of these pathways will lead to potential therapies for AD (Fig. 5).

Therapies targeting misfolding

Neurodegenerative diseases share common cellular and molecular mechanisms, such as protein aggregation and inclusion body formation. The protein aggregates consist of fibrils of misfolded amyloid proteins that have taken on β-sheet conformation. The formation of these aggregates can be prevented by two pathways: the Hsp40/Hsp60/Hsp70 pathway mediates protein aggregation, while the proteolytic system removes misfolded proteins [67]. Several agents may be able to target the protein misfolding pathway. For example, Congo red binds to proteins with β-sheet structures, alters the protein misfolding pathway and reduces toxicity in vivo [24, 68–71]. Recent therapeutic developments include peptides that interfere with the post-translational modifications that are responsible for the misfolding and aggregation of Aβ and tau. They also include the up-regulation of molecular chaperones to increase the clearance of protein aggregates [69]. Of the ATP-dependent endogenous proteasome activators (PA700, PA200 and PA28), targeting PA700 may be the most...
successful therapeutic approach for increasing misfolded protein degradation [79].

**Therapies targeting the different quality control systems of the cell**

Ubiquitin-dependent protein degradation occurs via two major catabolic systems: the endosomal/lysosomal system and the ATP-dependent, non-lysosomal proteolysis system, which is known as the UPS.

**Autophagy (the endosomal/lysosomal system)**

Through autophagy, lysosomes degrade normal and aggregated proteins that are usually found under conditions of stress or injury. Independent alterations in the endocytic pathway activate the lysosomal system and increase the number and density of lysosomes as well as gene expression [80]. The latter effect results in the synthesis of all classes of lysosomal hydrolases, including cathepsin [81]. Lysosomal cathepsin B is up-regulated either by the accumulation of proteins or by the modulator 2-Phe-Ala-diazomethyl ketone (PADK). Systemic administration of PADK increases cathepsin B activity, which increases the clearance of intracellular Aβ and decreases its extracellular deposition. PADK inhibits protein accumulation and promotes synaptic integrity *in vivo* and *in vitro* [82]. Thus, modulators of lysosomal activity show great promise for the treatment of neurodegenerative diseases.

Autophagy reduces the accumulation and facilitates the clearance of normal or mutant Aβ [80]. The Aβ that is generated in endosomes and autophagic vacuoles is delivered to lysosomes, where it is cleared through lysosomal proteolysis under normal conditions [83]. Enhanc-

**Table 1 Agents that target Aβ production or aggregation**

| Agents that decrease production of Aβ | Details | Agents under investigation | Status | Rel. |
|-------------------------------------|---------|----------------------------|--------|-----|
| β-secretase inhibitor               | MK8931  | NIC5-15                    | (III)* | [72]|
| γ-secretase inhibitor               | EVP0962 | CHF5074                    | (II)   |     |
| α-secretase activator               | Etzelfol EGCg |               | (IIA)  |     |

| Agents that decrease aggregation or oligomerization of Aβ | Anti-aggregation nanopeptide | Tramiprosate | (III) | [72, 73] |
|------------------------------------------------------------|-------------------------------|--------------|-------|----------|
| Fluorinated nanoparticles                                 |                               |              |       |----------|

*The status of a drug in an ongoing clinical trial.

**Table 2 Other agents that target Aβ metabolism**

| Targets of the agents | Details | Agents under investigation | Status | Rel. |
|-----------------------|---------|----------------------------|--------|-----|
| Apolipoprotein (ApoE) and Aβ clearance | Nuclear receptor modulator and ApoE activator | Bexarotene | – | [74] |
| Enzymes that degrade Aβ (NEP, IDE, ECE, ACE) | Increases NEP activity | Valproic acid | Dextrogen Green tea | – | [75] |
| Aβ transport | Antibodies against LRP | – | – | [76] |
| | Intraneuronal Aβ transport | Cerebrolysin | – | [77] |
| Aβ signaling | Blocks Fyn kinase or cellular prion proteins | Saracatinib | (II) | [76] |
| Intravenous immunoglobulin | Clearance of Aβ | – | – | [78] |
| Medications that influence Aβ blood–brain barrier transport | Inhibition of RAGE | – | – | [64] |
| | Activation of LRP-1 | – | – | [64] |
ing lysosomal proteolysis in TgCRND8 transgenic mice increased the clearance of autophagy substrates, which reduced intracellular and extracellular Aβ levels and reversed multiple cognitive deficits [84]. Rapamycin could be effective in preventing or reversing AD pathology, because it inhibits motor activity and enhances autophagy. Rapamycin also inhibits NFT formation and tau phosphorylation and reduces cognitive impairment [80]. Hence, drugs that induce autophagy could reduce or eliminate protein aggregates [85]. Impaired clearance and accumulation of autophagic vacuoles in AD-affected neurons causes abnormal autophagy [86, 87]; this effect might block the neuroprotective effect of autophagy and limit the accumulation of toxic proteins (including tau), thus promoting neuronal cell death [88].

**Molecular chaperones (Hsps)**

Molecular chaperones and the UPS are the first and second lines of defense against protein misfolding and aggregation. Chaperones regulate the folding of newly synthesized proteins and the refolding or transfer of misfolded proteins to protein degradation systems [22]. Lower molecular weight Hsps (12–43 kD) are ATP independent, whereas higher molecular weight Hsps (>43 kD) are ATP dependent. Several studies [89–93] have demonstrated that the chaperone network can be targeted to develop therapeutic strategies for AD [94]. Chaperones bind to Aβ and tau and regulate their degradation. Both Hsp90 and Hsp70 participate in APP metabolism [95]. Hsp70 is ATP dependent and the major target for AD treatment. Increased Hsp70 levels inhibit its ATPase activity and might be an effective treatment strategy for AD [94]. In 5XFAD transgenic mice, recombinant human Hsp70 reduces Aβ plaque formation [96]. At very high concentrations, methylene blue inhibits Hsp70 and increases tau clearance [68]. Curcumin was also shown to increase Hsp70 and Hsp90 activity, which could inhibit or delay amyloid formation and reduce neuronal death [97, 98]. The co-chaperone protein Bcl2-associated athanogene (BAG-1) forms a complex with Hsp70 and tau and could inhibit tau degradation [99] in cell cultures, increasing both tau and APP levels [99, 100].

Hsp90 regulates the misfolding and stabilization of neurotoxic proteins and facilitates tau pathology in AD [101]. Inhibiting Hsp90 reduces levels of hyperphosphorylated and Ser/Thr-mutated tau as well as of the kinases that are involved in persistent hyperphosphorylation [102]. Moreover, Hsp90 inhibition induces heat shock factor, Hsp70 and small heat shock proteins (sHsps). This inhibition also facilitates Hsp70 binding to abnormal proteins to form a complex that is ubiquitinated byCHIP (carboxyl C-terminus of Hsp70-interacting protein) and degraded through proteolysis. Thus, Hsp90 inhibition increases tau degradation and might be a potential therapeutic target

---

**Table 3 Immunotherapy-based agents**

| Agents | Details | Agents under investigation | Status | Ref. |
|--------|---------|-----------------------------|--------|-----|
| Active immunotherapy agents (Vaccine) | DNA vaccine | pCMVE/MDC-3A/11 PADRE-C3d | – | [103] |
| | Epitope-/protein-VLP-based vaccine | Adeno-10× Aβ3 – 10+ CpG | – | |
| | Prime-boost approach | Aβ1-42 peptide prime/Aβ1-42 DNA + QuilA | – | |
| Passive immunotherapy agents | Monoclonal antibody | Bapineuzumab Solanezumab | (III) | [64] |

**Table 4 Agents that target tau**

| Targets of the agents | Details | Agents under investigation | Status | Ref. |
|----------------------|---------|-----------------------------|--------|-----|
| Hyperphosphorylation | Kinase inhibitor GSK-3α GSK-3β CDK5 | Lithium AZD-1080 Minocycline Cerebrolysin | – | [64, 104] |
| | Inhibits histone deacetylase | HDAC6 | – | [73] |
| Microtubule stabilizers | Improves axonal transport, microtubule density | Epothilone NAP (NAPVSIPQ) D-SAL (SALLRSIPA) | – | [76] |
| Blocking tau oligomerization | Reduce tau-tau interactions | Astemizole Lansoprazole Methylene blue | – | |
| Enhancing tau degradation | Inhibit heat shock protein 90 | Curcumin | – | |
| Vaccination therapy | Promote immunological clearance of tau | – | – | |

© 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
for tau-based neurodegeneration in AD [101]. The antibiotic geldanamycin was the first Hsp90 inhibitor to be identified; geldanamycin was shown to compete with ATP and stop neurotoxic protein folding and stabilization [105, 86, 87, 106]. Although geldanamycin is toxic and cannot penetrate the blood–brain barrier, other agents have been developed. 17-AAG and PU-DZ8 are synthetic purine scaffold proteins that cross the blood–brain barrier, inhibit Hsp90, and decrease levels of phosphorylated tau [107].

### The ubiquitin proteasomal system

The role of the UPS in AD has been demonstrated through observations of the downregulation of E1 and E2 enzymes, the oxidation of DUBs, the accumulation of mutated ubiquitin, the detection of proteasome subunits and decreased proteasomal activity [43]. Toxic Aβ is formed when β-secretase cleaves APP and generates a C-terminal fragment (APPCTFB or C99). This fragment is subsequently cleaved by γ-secretase to produce toxic Aβ40 and Aβ42. Proteasome inhibitors up-regulated APP C99, suggesting that they may decrease β-secretase activity [62].

### UPS components as potential therapeutic targets in AD management

In the pathogenesis of AD, it remains unclear whether Aβ accumulation causes UPS dysfunction or vice versa [13, 92].

The 26S proteasome ubiquinates and degrades proteins other than β- and γ-secretase that are involved in APP metabolism [20]. The overexpression of an APP mutant isoform has been correlated with increased oxidative stress and decreased proteasome activity [84]. Moreover, proteins associated with AD (most notably AHNAK, gelsolin and tenascin-R) were found to exhibit strong interactions with ubiquitin C. This change in AD associated proteins was observed in regions that are frequently affected in AD (the hippocampus, parietal cortex and cerebellum), suggesting that ubiquitin C promotes age-related neurodegeneration [108]. Aβ40 and Aβ42 oligomers, but not their monomers, also inhibit proteasomal activity in cell-free assays [22].

The UPS processes and degrades presenilin-1 (ps-1), presenilin-2 (ps-2) and mutated presenilin, which are key proteins in the pathogenesis of AD. Therefore, proteasomes and mutated presenilin might indirectly influence Aβ production [30]. Ubiquilin regulates UPS activity and presenilin metabolism. It decreases γ-secretase activity and downregulates presenilin and its N-terminal and C-terminal fragments [13]. Ubiquilin-1 is functionally associated with AD and interacts with both ps-1 and ps-2 [13].

The UPS ubiquinates and degrades β-secretase [109]. Up-regulating proteasomal degradation of β-secretase and γ-secretase decreases Aβ levels. Proteasome activation can also be used to clear tau [85]. Hence, the UPS may provide an alternative target for new therapies for AD [13]. An age-dependent decrease in proteosomal activity may cause both Aβ and tau to accumulate. Once Aβ and tau aggregates are formed, they decrease proteasome activity and create a vicious cycle that increases Aβ and tau accumulation [110]. Normal tau in the normal brain and hyperphosphorylated and misfolded tau in the AD brain are present at both pre- and postsynaptic terminals [111]. Abnormally folded and hyperphosphorylated tau accumulates in dendrites, axons and somas [112]. In addition, changes in proteasomal subunit composition alter proteasomal activity in AD [33]. Thus, tau oligomers might accumulate in AD synapses because of increased proteosomal components and UPS dysfunction [111]. BAG-1 and Hsp70 regulate the proteosomal degradation of tau [22]. Kinases (such as glycogen synthase kinase-3 and casein kinase-1) phosphorylate tau [26] and might be candidate therapeutic targets for AD. Tau co-immunoprecipitates with CHIP, an E3 ubiquitin ligase that ubiquinates tau before the proteasome degrades it. Phosphorylated tau accumulates in the neurons of CHIP knockout mice and inhibits the interaction between tau and CHIP in AD [113]. In vitro studies of AD brains showed that high CHIP levels were associated with less tau aggregation and fewer NFTs [114]. In addition, the CHIP knockout

### Table 5 Agents that target neurotransmitter signaling

| Targeted neurotransmitter | Agents under investigation | Status | Ref. |
|---------------------------|----------------------------|-------|-----|
| Acetylcholine              | Latrepirdine               | (III) | [76]|
|                           | Huperzine A                |       |     |
| GABA                      | SGS742                     | (II)* |     |
|                           | ADS-8704 (NMDA antagonist)  | (III) |     |
| Serotonin                 | 5HT1A                      | (II)  |     |
|                           | Lecozotan                  |       |     |
|                           | 5-HT4                      | –     |     |
|                           | PRX-03140                  |       |     |
|                           | TD-955                     |       |     |
|                           | SB-742457                  | (II)  |     |
| Histamine                 | PF08654746                | (I)   |     |
|                           | AB288                      | (II)  |     |
| Adenosine                 | SCH58261                   | –     |     |
mice showed the accumulation of species of phosphorylated tau [113]. Thus, the proteasome is directly involved in NFT accumulation, and reduced proteasomal activity might cause tangle formation in patients with AD [43].

Ubiquitin C-terminal hydrolase 1 is oxidized and downregulated in AD [110], and UCHL1 inhibition up-regulates \( \beta \)-secretase. UCHL1 also accelerates \( \beta \)-secretase degradation, impairs APP processing and decreases \( \beta \)-amyloid [109]. Furthermore, the synaptic dysfunction that is induced by \( \beta \)-amyloid can be reduced by increasing UCHL1 expression [110]. Hence, UCHL1 is a promising target for the development of therapeutic agents for AD.

### Importance of UPP in the management of Alzheimer’s disease

Amyloid beta neurotoxicity inhibits the proteasome in association with increased brain levels of E2-25k/ Hip-2. E2-25k/ Hip-2-mediated proteasome inhibition can directly induce neuronal death and indirectly increase \( \beta \)-amyloid production [45]. In vitro, E2-25k/ Hip-2-mediated ubiquitination of a mutated form of ubiquitin (UBB+1) at Lys48 was suggested to inhibit proteasome activity [87]. In vitro, cultures exposed to \( \beta \)-amyloid up-regulate E2-25k/ Hip-2 expression in neurons [117]. E2-25k/ Hip-2 induction is required for neuronal cell death under \( \beta \)-amyloid toxicity. It inhibits proteasome activity and promotes the accumulation of ubiquitin conjugates, which increases the levels of apoptosis signal regulating kinase-1/C-Jun N-terminal kinase and leads to \( \beta \)-amyloid neurotoxicity. Therefore, E2-25k/ Hip-2 might be a potential therapeutic target in AD [118].

Ubiquitin is an endogenous reporter of proteasome activity in human AD pathology and can inhibit proteasomal degradation [43]. Current studies have shown that UBB+1 accumulates in the brains of AD patients [43]. UBB+1 is selectively expressed in neurons and competes with normal ubiquitin for binding to proteasomal target proteins. It also interacts with E2-25k/ Hip-2 to inhibit the 26S proteasome and block ubiquitin-dependent proteasomal proteolysis [61, 119]. Polyubiquitin chains that contain UBB+1 are refractory to DUB lysis and alter proteasomal degradation of the substrate [120]. UBB+1 also impairs mitochondrial movement and promotes neurodegeneration in primary neurons [121]. Proteasome-associated proteins contribute to the proteasome’s proteolytic function and regulate its activity through calcium signaling. The function of these proteasome-associated proteins was also impaired in AD brains [30].

The loss of proteasome activity with age leads to decreased subunit expression, alterations and replacement of proteasome subunits and the formation of inhibitory cross-linked proteins [122]. In transgenic (Tg2576) mice, ubiquitin and proteasome activity decreased with age, whereas \( \beta \)-amyloid levels increased. In addition, in cultured neurons, extracellular administration of \( \beta \)-amyloid markedly decreased proteasome activity [123].

### Recent therapeutic developments

Enhancing chaperone function, chaperone up-regulation and aggregate clearance or targeting post-translational modifications (inhibiting oxidation and phosphorylation) could inhibit protein misfolding and aggregation. For example, current AD therapeutic strategies that target Hsp70 include the induction of endogenous Hsp70, exogenous

---

**Table 6: Agents that target cellular metabolic pathways**

| Agents | Details | Agents under investigation | Status | Ref. |
|--------|---------|----------------------------|--------|-----|
| Agents that target intracellular signaling cascades | Phosphodiesterase inhibitor | AVE-8112, BCA-909, THPP-1 | – | [76] |
| | Lipoprotein inhibitor | Rilapludib (NCT01428453) | (I/II) | |
| Agents that target mitochondrial dysfunction | Mitochondrial-targeted ROS scavenger therapy | Szo5-schiller peptide (SS-31) | – | |
| | Lipoic acid omega-3 fatty acid combination therapy | NCT01780974, NCT01058941 | (I/II) | |
| Agents that target epigenetics | DNA methylation and histone modification | Vitamin B | – | [115] |
| Agents that target oxidative stress | Vitamin E + selenium | NCT00040378 | (III) | |
| | Melatonin | NCT00945089 | (II) | |
| Caspase inhibitors | Neuroprotective benefits | – | – | |
| Metal chelators | Inhibit zinc and copper from binding to \( \beta \)-amyloid | Clioquinol | (II) | [116] |
| | Metal protein attenuation | PBT2 | (II) | |

ª 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Hsp70 utilization and Hsp70 inhibition. The combination of agents that affect more than one of these therapeutic targets will be the most effective treatment strategy for AD [69].

E3 enzymes determine the specificity of UPS-mediated proteolysis. Hence, identifying their specific allosteric modulators could provide an effective therapeutic target [21, 69]. PROTACS (proteolysis-targeting chimeric molecules) bind to E3 ubiquitin ligases. They promote the synthesis and attachment of the poly-ubiquitin chain to the target protein, which is followed by protein degradation by the 26S proteasome. Therefore, developing PROTACS could prevent the accumulation and aggregation of tau proteins [128].

**Table 7 Agents with other targets**

| Agents                                      | Details                                      | Agents under investigation | Status | Ref.  |
|---------------------------------------------|----------------------------------------------|-----------------------------|--------|-------|
| Glial cell modulators                       | Direct glial target                          | ONO-2506                    |        | [64]  |
| Anti-inflammatory agents                    | NSAID                                        | CHF5074 and SC560           |        |       |
| Cholesterol-lowering agents                 | Pleiotropic effect                           | Simvastatin                 | (III)  | [116] |
| Neurogenesis                                | Pleiotropic effect                           | Cerebrolysin                |        | [76]  |
| Multi-target-directed ligands               | Multifunctional compound                     | Ladostigil (TV3326)         |        |       |
| Neurotrophins                               | NGF brain delivery via adeno-associated virus vector system | CERE-110 NCT00876863 NCT00087789 | (I)*   | [124] |
| Based on stereotactic implantation containing NGF-producing cell | NsG0202 | (I) | | |
| Nutritional supplements                     | Combination medical food                     | Souvenaid®                  |        | [125] |
| Natural products, e.g. quercetin             |                                              |                             |        |       |
| Neuroprotective gonadotropin hormone         |                                              |                             |        | [76]  |
| NOS modulators                              |                                              |                             |        |       |
| Nucleic acid agents                         |                                              |                             |        |       |
| Agents that modulate synaptic plasticity and nerve growth | | | | |
| Stem cells                                  |                                              |                             |        | [127] |

*The status of a drug in an ongoing clinical trial.

Hsp70 utilization and Hsp70 inhibition. The combination of agents that affect more than one of these therapeutic targets will be the most effective treatment strategy for AD [69].

E3 enzymes determine the specificity of UPS-mediated proteolysis. Hence, identifying their specific allosteric modulators could provide an effective therapeutic target [21, 69]. PROTACS (proteolysis-targeting chimeric molecules) bind to E3 ubiquitin ligases. They promote the synthesis and attachment of the poly-ubiquitin chain to the target protein, which is followed by protein degradation by the 26S proteasome. Therefore, developing PROTACS could prevent the accumulation and aggregation of tau proteins [128].

Resveratrol is a phytoalexin polyphenolic compound (trans-3, 4, 5-trihydroxystilbene) from grapes and wines. As a result of its anti-amyloidogenic activity, resveratrol might show therapeutic potential in AD [129]. Resveratrol promotes neuroprotection via multiple mechanisms [13]: it inhibits Aβ aggregation, scavenges oxidants, reduces inflammation [13] and removes Aβ via the proteasomal pathway [129].

Betulinic acid, a lupine-type pentacyclic triterpene derived from birch trees, activates the chymotrypsin-like activity of the proteasome [130]. Overexpressing arsenite-inducible RNA-associated protein, which stabilizes proteasome activity in the absence of ATP [131], is another therapeutic approach to maintain proteasome function.

**Future prospects**

Emerging evidence suggests that the substrate-specific components of the UPS, such as the E3 ligase, may impair ubiquitination, which results in UPS aberrations, defective proteasome-mediated protein degradation, the accumulation of toxic proteins and neuronal death. Studies of the interaction between Aβ and the proteasomal system have shown that Aβ(40) binds directly to the inside of the 20S proteasome, blocks the peptide channel and inhibits the chymotrypsin-like activity of proteasome
Tau accumulation also inhibits the proteasome and reduces protein degradation [18, 133]. Several proteases break down tau, including calpain; caspases 3, 6 and 9; cathepsin D and L; and puromycin-sensitive aminopeptidase. These proteases limit tau proteolysis and may contribute to AD pathology. However, they may also be potential therapeutic targets for this disease [134].

The development of proteasome activators is another potential approach to prevent Aβ accumulation in AD [135]. Proteasome-activating peptide 1 increases the chymotrypsin-like activity of the proteasome in fibroblast cell cultures. It also down-regulates and prevents the aggregation of oxidized proteins in amyotrophic lateral sclerosis [135].

USP14, a proteasome-associated DUB, inhibits the degradation of ubiquitin-protein conjugates both in vivo and in vitro. USP14 inhibits proteasome activity by trimming the ubiquitin chain on the substrate. Inhibition of USP14 accelerates the degradation of oxidized proteins and increases cell resistance to oxidative stress [136]. IU1 is a chain-trimming enzyme that inhibits USP14 and prevents the rescue of ubiquitinated forms of the neurotrophic proteins tau and ataxin. IU1 acts on the proteasome and was found to have a therapeutic benefit in AD [14]. IU1 was also shown to promote the degradation of several overexpressed proteins (tau, TDP-43 and ATXN3) in various neurodegenerative diseases [27]. As ubiquitin chain trimming can promote or inhibit proteasomal degradation, future studies should identify whether IU1 inhibits other DUBs or proteases in human cells [27].

Fig. 5 Approaches for the management of Alzheimer’s disease. Inhibitors of the 26S proteasome cause Aβ and tau aggregation, which impairs proteasomal function and promotes the accumulation of Aβ and tau in neurons, resulting in neuronal death and Alzheimer’s disease. ATP hydrolysis is necessary for both ubiquitination and 26S proteasomal degradation of ubiquitinated proteins. UBB+1 is selectively expressed in neurons and competes with normal ubiquitin for binding to target proteins. UBB+1 blocks ubiquitin-dependent proteolysis by interacting with E2-25k/Hip-2 and might induce neurotoxicity and the abnormal accumulation of proteins. BAG1 and Hsp70 regulate the proteasomal degradation of tau. UCHL1 accelerates β-secretase degradation and affects APP processing and Aβ production. USP14 inhibits proteasome activity. Aβ40 and Aβ42 oligomers decrease the trypsin-like, chymotrypsin-like and peptidyl/glutamyl-like activity of the proteasome and promote intraneuronal accumulation of Aβ conjugates. Low levels of CHIP promote the accumulation of phosphorylated tau species, inhibiting the proteasome and decreasing protein degradation.

The UPS and its components are key factors in AD treatment. The UPS mediates the pathogenesis of AD through various mechanisms. Full understanding of the mechanisms of proteasomal activity is critical for the development of improved therapeutic and diagnostic strategies for managing AD. The development of effective medications also requires comprehensive understanding of the role of proteasome inhibition and how neuronal death occurs in patients with AD. Amyloid beta has been shown to inhibit proteasomes in vitro, even though it remains unclear whether AD patients show the same pattern. Future AD therapies should reduce protein aggregation by targeting specific components of the UPS (e.g. the 26S proteasome, ubiquitin and DUBs). Another strategy could be to enhance proteasome activity by inhibiting USP14. To develop new therapies for AD, we need to fully understand how the components of the UPS interact in protein degradation.

Acknowledgements

The authors are grateful to Dr. Mangala Lahkar, Coordinator of Institutional Level Biotech hub (IBT hub), NIPER Guwahati, for her support and to her superb staff for their helpful discussions. We would also like to acknowledge Dr. Maria Balea from the ‘RoNeuro’ Institute for Neurological Research and Diagnostic for English knowledge expertise.

Conflicts of interest

All of the authors declare that they have no potential conflicts of interest to disclose.
References

1. Brockwell DJ, Radford SE. Intermediates: ubiquitous species on folding energy landscapes? Curr Opin Struct Biol. 2007; 17: 30–7.

2. Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 2015; 47: e147.

3. Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell. 2006; 125: 443–51.

4. Zhao Y, Maagurn JA, Liu M, et al. The ART-Rps5 ubiquitin ligase network comprises a plasma membrane quality control system that protects yeast cells from proteotoxic stress. Elife. 2013; 2: e00459.

5. David CR. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006; 443: 780–6.

6. Lim J, Yue Z. Neuronal aggregates: formation, clearance, and spreading. Dev Cell. 2015; 32: 491–501.

7. Zheng C, Geetha T, Babu JR. Failure of ubiquitin proteasome system: risk for neurodegenerative diseases. Neurodegener Dis. 2014; 14: 161–75.

8. Koulich E, Li X, DeMartino GN. Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Mol Cell Biol. 2008; 19: 1072–82.

9. Kohler A, Bajorek M, Groll M, et al. The substrate translocation channel of the proteasome. Biochimie. 2001; 83: 325–32.

10. Alexandra E, Luis S, Manuela LP. The amyloid stretch hypothesis: recruiting proteins toward the dark side. PNAS. 2005; 102: 16672–7.

11. Stadtmueller BM, Hill CP. Proteasome activators. Mol Cell. 2011; 41: 8–19.

12. Upadhye SC, Hegde AN. Role of the ubiquitin proteasome system in Alzheimer’s disease. BMC Biochem. 2007; 8 (Suppl. 1): S12.

13. Hong L, Huang HC, Jiang ZF. Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer’s disease. Neurol Res. 2014; 36: 276–82.

14. Ristic G, Tsou WL, Todi SV. An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes. Front Mol Neurosci. 2014; 7: 72.

15. Dantuma NP, Bott LC. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci. 2014; 7: 70.

16. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov. 2006; 5: 596–613.

17. Tai H-C, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci. 2008; 9: 826–36.

18. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol. 2006; 3: 255–61.

19. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 2006; 17: 1807–19.

20. Xie Y. Structure, assembly and homeostatic regulation of the 26S proteasome. J Mol Cell Biol. 2010; 2: 308–17.

21. Eldridge AG, O’Brien T. Therapeutic strategies within the ubiquitin proteasome system. Curr Drug Discov. 2010; 17: 4–13.

22. Morawe T, Hiebel C, Kern A, et al. Protein homeostasis, aging and Alzheimer’s disease. Mol Neurobiol. 2012; 46: 41–54.

23. Komander D, Claque MJ, Urse S. Breaking the chains: structure and function of the deubiquitinasens. Nat Rev Mol Cell Biol. 2009; 10: 550–63.

24. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003; 426: 895–8.

25. Nguyen LK, Dobryzinski M, Fey D, et al. Polyubiquitin chain assembly and organization determine the dynamics of protein activation and degradation. Front Physiol. 2014; 5: 4.

26. Lehman NL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol. 2009; 118: 329–47.

27. Liu CW, Jacobson AD. Functions of the 19S complex in proteasomal degradation. Trends Biochem Sci. 2013; 38: 103–10.

28. Balakirev MY, Tcherniuk SO, Jauquind M, et al. Ubilains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep. 2003; 4: 517–22.

29. da Fonseca PC, Morris EP. Structure of the human 26S proteasome: subunit radial displacements open the gate into the proteolytic core. J Biol Chem. 2008; 283: 23305–14.

30. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer’s disease. J Neurochem. 2000; 75: 436–9.

31. Wojcik C, DeMartino GN. Intracellular localization of proteasomes. Int J Biochem Cell Biol. 2003; 35: 579–89.

32. Liu C-W, Li X, Thompson D, et al. ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol Cell. 2006; 24: 39–50.

33. Mishto M, Bellavista E, Santoro A, et al. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer’s disease brains. Neurobiol Aging. 2008; 27: 54–66.

34. Orre M, Kamphuis W, Dooves S, et al. Reactive glia show increased immunoproteasome activity in Alzheimer’s disease. Brain. 2013; 136: 1415–31.

35. Tanaka K. The proteasome: overview of structure and function. Proc Jpn Acad Ser B Physioll Sci. 2009; 85: 12–36.

36. Massaly N, Frances B, Mouleous L. Roles of the ubiquitin proteasome system in the effects of drugs of abuse. Front Mol Neurosci. 2015; 7: 99.

37. Ferrington DA, Gregerson DS. Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci. 2012; 109: 75–112.

38. Bar-Nun S, Glickman MH. Proteasomal AAA-ATPases: structure and function. Biochim Biophys Acta. 2012; 1823: 67–82.

39. Bedford L, Paine S, Sheppard PW, et al. Assembly, structure, and function of the 26S proteasome. Trends Cell Biol. 2010; 20: 391–401.

40. Cox O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996; 65: 801–47.

41. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie. 2001; 83: 301–10.

42. Jung T, Grune T. The proteasome and the degradation of oxidized proteins: part I—structure of proteasomes. Redox Biol. 2013; 1: 178–82.

43. Hol EM, van Leeuwen FW, Fischer DF. The proteasome in Alzheimer’s disease and Parkinson’s disease: lessons from ubiquitin B + 1. Trends Mol Med. 2005; 11: 488–95.

44. Voges D, Zwicki P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 1999; 68: 1015–68.

45. Lee S-H, Moon J-H, Yoon SK, et al. Stable incorporation of ATPase subunits into 19S regulatory particle of human proteasome requires nucleotide binding and C-terminal tails. J Biol Chem. 2012; 287: 9269–79.

46. Ciechanover A. Intracellular protein degradation: from a vague idea thru

© 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
lyosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 2005; 12: 1178–90.

47. Rabl J, Smith DM, Yu Y, et al. Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell. 2008; 30: 360–8.

48. Benaroudj N, Zwicki P, Seemüller E, et al. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol Cell. 2003; 11: 69–78.

49. Lu Y, B-h Lee, King RW, et al. Substrate degradation by the proteasome: a single-molecule kinetic analysis. Science. 2015; 348: 1250834.

50. Hegde AN, Upadhya SC. Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. Biochim Biophys Acta. 2011; 1809: 128–40.

51. Majdi S, Power JH, Grantham HJ. Neuronal response in Alzheimer’s and Parkinson’s disease: the effect of toxic proteins on intracellular pathways. BMC Neurosci. 2015; 16: 69.

52. Rahaman M, Zetterberg H, Lendel C, et al. Binding of human proteins to amyloid-beta protofibrils. ACS Chem Biol. 2015; 10: 766–74.

53. Ying Z, Wang H, Wang G. The ubiquitin proteasome system as a potential target for the treatment of neurodegenerative diseases. Curr Pharm Des. 2013; 19: 3305–14.

54. Daniels RW, Miller BR, DiAntonio A. Increased vesicular glutamate transporter expression causes excitotoxic neurodegeneration. Neurobiol Dis. 2011; 41: 415–20.

55. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010; 460: 525–42.

56. Johnson DA, Johnson JA. Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med. 2015; 88: 253–67.

57. Cabezas-Ojeda FA, et al. Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev. 2015; 2015: 509654.

58. Engel PA. Does metabolic failure at the synapse cause Alzheimer’s disease? Med Hypotheses. 2014; 83: 802–8.

59. Sensi S. Metal homeostasis in dementia. Free Radiat Biol Med. 2014; 75 (Suppl. 1): S9.

60. Hegde AN. The ubiquitin-proteasome pathway and synaptic plasticity. Learn Mem. 2010; 17: 314–27.

61. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest. 2002; 82: 965–80.

62. Qing H, Zhou W, Christensen MA, et al. Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J. 2004; 18: 1571–3.

63. Salomone S, Caraci F, Leggio GM, et al. New pharmacological strategies for treatment of Alzheimer’s disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2012; 73: 504–17.

64. Aprahamian I, Stella F, Forlenza OV. New treatment strategies for Alzheimer’s disease: is there a hope? Indian J Med Res. 2013; 138: 449–60.

65. Gavrilova SI, Kolykhlov IV, Fedorova YB, et al. Possibilities of preventive treatment of Alzheimer’s disease: results of the 3-year open prospective comparative study on the efficacy and safety of the course therapy with cerebrosylin and cavinton in elderly patients with the syndrome of mild cognitive impairment. Treatment of neurological and psychiatric diseases. 2010; 110: 62.

66. Fragoso YD, Dantas DC. Cerebrosylin for Alzheimer’s disease. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003801.

67. Paul S. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. BioEssays. 2008; 30: 1172–84.

68. O’Leary JC, Li Q, Marinec P, et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener. 2010; 5: article 45.

69. Rochel JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med. 2007; 9: 1–34.

70. Ross C, Poirier M. Protein aggregation and neurodegenerative disease. Nature Med. 2004; 10: S10–7.

71. Upadhya SC, Hegde AN. Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies. Curr Pharm Des. 2005; 11: 407–20.

72. Ouital L, Yulin D, Hong Q. Potential therapeutic strategies for Alzheimer’s disease targeting or beyond β-amyloid: insights from clinical trials. BioMed Research International. 2014; 2014: 22.

73. Saraiva A, Cardoso I, Pereira MC, et al. Controlling amyloid-beta peptide (1–42) oligomerization and toxicity by fluorinated nanoparticles. ChemBioChem. 2010; 11: 1905–13.

74. Katherine DL, Kebreth FM, Dexter LL, et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener. 2013; 8: 18.

75. Miners JS, Barua N, Kehoe PG, et al. Amyloid degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 2011; 70: 944–59.

76. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015; 67: 195–203.

77. Edward R, Magdalena T, Michael M, et al. Cerebrosylin decreases amyloid-β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer’s disease. J Neurosci Res. 2006; 83: 1252–61.

78. Nyaaga HB. Current and emerging therapies for Alzheimer’s disease. Clin Ther. 2013; 35: 1480–9.

79. Verma R, Peters NR, D’Onofrio M, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science. 2004; 306: 117–20.

80. Cai Z, Yan L.J. Ramapycin, autophagy, and Alzheimer’s disease. J Biochem Pharmacol Res. 2013; 1: 64–90.

81. Nixon RA, Mathews PM, Cataldo AM. The neuronal endosomal-lysosomal system in Alzheimer’s disease. J Alzheimers Dis. 2001; 3: 97–107.

82. Butler D, Nixon RA, Bahr BA. Potential compensatory responses through autophagic-lysosomal pathways in neurodegenerative diseases. Autophagy. 2006; 2: 234–7.

83. Yang D-S, Stavrides P, Mohan PS, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits. Brain. 2011; 134: 258–77.

84. Cecarini V, Bonilli L, Cuccioloni M, et al. Crosstalk between the ubiquitin–proteasome system and autophagy in a human cellular model of Alzheimer’s disease. Biochim Biophys Acta. 2012; 1822: 1741–51.

85. Lane RF, Shineman DW, Steele JW, et al. Beyond amyloid: the future of therapeutics for Alzheimer’s disease. Adv Pharmacol. 2012; 64: 213–71.

86. Boland B, Kumar A, Lee S, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci. 2008; 28: 6926–37.

87. Eskelinen E-L, Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta. 2009; 1793: 664–73.

88. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007; 120: 4081–91.

© 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
89. Blair LJ, Sabbagh JJ, Dickey CA. Targeting Hsp90 and its co-chaperones to treat Alzheimer’s disease. Expert Opin Ther Tar. 2014; 18: 1219–32.

90. Ou J-R, Tan M-S, Xie A-M, et al. Heat shock protein 90 in Alzheimer’s disease. Biomed Res Int. 2014; 1–7.

91. Salminen A, Ojala J, Kaarniranta K, et al. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer’s disease. Prog Neurobiol. 2011; 93: 99–110.

92. Takalo M, Haapasalo A, Nalunen T, et al. Targeting ubiquitin-1 in Alzheimer’s disease. Expert Opin Ther Tar. 2013; 17: 795-810.

93. Wilhelmus MM, De Waal RM, Verbeek MM. Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer’s disease. Mol Neurobiol. 2007; 35: 203–16.

94. Jinwal UK, Koren J, O'Leary JC, et al. Hsp70 ATPase modulators as therapeutics for Alzheimer’s and other neurodegenerative diseases. Mol Cell Pharmacol. 2010; 2: 43–6.

95. Gao X, Hu H. Quality control of the proteins associated with neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai). 2008; 40: 612–6.

96. Bobkova NV, Garbus DG, Nesterova I, et al. Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer’s disease. J Alzheimers Dis. 2014; 38: 425–35.

97. Malti P, Manna J, Veleri S, et al. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. Biomed Res Int. 2014; 2014: 490591.

98. Mishra S, Palanivelu K. The effect of curcumin (tumeric) on Alzheimer’s disease: an overview. Ann Indian Acad Neurol. 2008; 11: 13.

99. Elliott E, Lauter O, Ginzburg I. BAG-1M is up-regulated in hippocampus of Alzheimer’s disease patients and associates with tau and APP proteins. J Neurochem. 2009; 109: 1168–78.

100. Elliott E, Tavkelov P, Ginzburg I. BAG-1 associates with Hsc70-Tau complex and regulates the proteasomal degradation of Tau protein. J Biol Chem. 2007; 282: 37276–84.

101. Carman A, Kishinevsky S, Koren J 3rd, et al. Chaperone-dependent neurodegeneration: a molecular perspective on therapeutic intervention. J Alzheimers Dis Parkinsonism. 2013; 2013: (suppl10), pii:007.

102. Jinwal UK, Trotter JH, Abisambra JF, et al. The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. J Biol Chem. 2011; 286: 16976–83.

103. Alices RPS, Yang MJ, Batista MT, et al. Alzheimer’s disease: is a vaccine possible? Braz J Med Biol Res. 2014; 47: 438–44.

104. Ubhi K, Rockenstein E, Doppler E, et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AA252-mutant Tau: neuroprotective effects of Cerebrolysin. Acta Neuropathol. 2009; 117: 699–712.

105. Chourak V, Seshadri S. Genetics of Alzheimer’s disease. Adv Genet. 2014; 87: 245–94.

106. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998; 42: 273–9.

107. Luo W, Dou F, Rodina A, et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. PNAS. 2007; 104: 9511–6.

108. Manavalan A, Mishra M, Feng L, et al. Brain site-specific proteome changes in aging-related dementia. Exp Mol Med. 2013; 45: e39.

109. Zhang M, Deng Y, Luo Y, et al. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem. 2012; 120: 1129–38.

110. Oddo S. The ubiquitin-proteasome system in Alzheimer’s disease. J Cell Mol Med. 2008; 12: 363–73.

111. Tai H-C, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012; 181: 1426–35.

112. Avila J, Lucas JJ, Perez M, et al. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004; 84: 361–84.

113. Dickey CA, Yue M, Lin W-L, et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho-and caspase-3-cleaved tau species. J Neurosci. 2006; 26: 6985–96.

114. Sahara N, Murayama M, Mizoroki T, et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem. 2005; 94: 1254–63.

115. Casey C, Jeannette NS, Yari C, et al. Acetylation: a new key to unlock tau’s role in neurodegeneration. Alzheimers Res Ther. 2014; 6: 29.

116. Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2011; 4: 203–16.

117. Salon ML, Pasquini L, Moreno MB, et al. Relationship between β-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol. 2003; 180: 131–43.

118. Song S, Kim S-Y, Hong Y-M, et al. Essential role of E2-25K/Hip-2 in mediating amyloid-β neurotoxicity. Mol Cell. 2003; 12: 553–63.

119. De Vrij FM, Slujs JA, Gregori L, et al. Mutant ubiquitin expressed in Alzheimer’s disease causes neuronal death1. FEBS J. 2001; 15: 2680–8.

120. Huang Q, Figueroa-Pereira ME. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis. 2010; 15: 1292–311.

121. Tan Z, Sun X, F-y Hou, et al. Mutant ubiquitin found in Alzheimer’s disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ. 2007; 14: 1721–32.

122. Carrard G, Bulteau AL, Petropoulos I, et al. Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol. 2002; 34: 1461–74.

123. Oh S, Hong HS, Hwang E, et al. Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech Ageing Dev. 2005; 126: 1292–9.

124. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010; 9: 702–16.

125. Swaminathan A, Jicha GA. Nutrition and prevention of Alzheimer’s dementia. Front Aging Neurosci. 2014; 6: 282.

126. Regitz C, Dubling LM, Wenzel U. Amyloid-beta (Aβ) (1–42)-induced paralysis in Caenorhabditis elegans is inhibited by the polyphenol quercetin through activation of protein degradation pathways. Mol Nutr Food Res. 2014; 58: 1931–40.

127. Abdel-Salam OM. Stem cell therapy for Alzheimer’s disease. CNS Neurol Drug Targets. 2011; 10: 459–85.

128. Schneekloth AR, Pucheault M, Tae HS, et al. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg Med Chem Lett. 2008; 18: 5904–8.

129. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer’s disease amyloid-β peptides. J Biol Chem. 2005; 280: 37377–82.

130. Huang L, Ho P, Chen CH. Activation and inhibition of the proteasome by betulinic acid and its derivatives. FEBS Lett. 2007; 581: 4955–9.

131. Stanhill A, Haynes CM, Zhang Y, et al. An arsenite-inducible 195 regulatory par-
article-associated protein adapts proteasomes to proteotoxicity. Mol Cell. 2006; 23: 875–85.

132. Gregori L, Hainfeld JF, Simon MN, et al. Binding of amyloid beta protein to the 20 S proteasome. J Biol Chem. 1997; 272: 58–62.

133. Tseng BP, Green KN, Chan JL, et al. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging. 2008; 29: 1607–18.

134. Wang Y, Mandelkow E. Degradation of tau protein by autophagy and proteasomal pathways. Biochem Soc Trans. 2012; 40: 644–52.

135. Dal Vechio FH, Cerqueira F, Augusto O, et al. Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced protein aggregation. Free Radic Biol Med. 2014; 67: 304–13.

136. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010; 467: 179–84.